PPD/Applied Bioscience (Pharmaco) merger will create third largest contract research organization.
PPD/APPLIED BIOSCIENCE MERGER TO CREATE THIRD LARGEST CRO with contract research "net revenue in excess of $150 mil.," the companies reported following signing of the merger agreement June 20. Total net revenue for the combined company will be $200 mil. The combined company will keep the Pharmaceutical Product Development name and headquarters in Wilmington, N.C. Applied Bioscience, a holding company headquartered in Arlington, Va., comprises the CRO Pharmaco International, the investigative site Chicago Center for Clinical Research, and an environmental sciences group, Environ, offering chemical and environmental health risk assessment.
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
The Center for Biologics Evaluation and Research saw departures far outnumber new hires in the second and third quarters of FY 2025, before more than 100 people left July 14 after the reduction-in-force was finalized.
US FDA's cancer drugs division is feeling the effect of drug reviewer departures, despite efforts to keep them at the agency.
Reforming clinical trial regulations, addressing the use of artificial intelligence, mitigating medicines shortages and strengthening ties with other drug regulators are key priorities for Australia’s Therapeutic Goods Administration over the next year.